David  Hung net worth and biography

David Hung Biography and Net Worth

CEO of Nuvation Bio

Dr. Hung founded Nuvation Bio in 2018 and serves as President and Chief Executive Officer and member of the Board of Directors.

Dr. Hung founded Medivation, Inc., in 2003, raising a total of $433 million in public offerings over the life of the company to reach a market cap of more than $14 billion, providing investors with a return on investment of 21,000%. In 2016, Medivation was sold to Pfizer for $14.3 billion in an all-cash deal, one of the largest biopharma sales ever by a founding Chief Executive Officer. For his role in creating Medivation, Dr. Hung was named the Life Sciences category winner and Overall U.S. winner across all categories of the 2014 Ernst & Young Entrepreneur of the Year Award.

Dr. Hung identified, in-licensed and led bench-to-bedside development of enzalutamide (XTANDI®) for advanced prostate cancer. At Medivation, XTANDI was taken from first in vitro laboratory experiment to FDA approval in seven years, one of the fastest development timelines in pharmaceutical history. XTANDI, approved in 60+ countries, reached blockbuster drug status, reaching nearly $6 billion in global annual sales in 2023.

At Medivation, Dr. Hung identified, in-licensed and developed talazoparib, a potentially best-in-class PARP inhibitor, which was approved by the FDA in October 2018, and the immune-oncology agent, pidilizumab, which demonstrated robust effects in Phase 2 studies and is now a promising Phase 3-ready asset.

Between Medivation and founding Nuvation Bio, Dr. Hung served for 10 months as Chief Executive Officer at Axovant Sciences before tendering his resignation. Prior to founding Medivation, he served as President and Chief Executive Officer of ProDuct Health, Inc., a venture-backed startup medical device company founded in 1998 that developed, manufactured and commercialized a breast microcatheter – that he invented – for breast cancer risk assessment. ProDuct Health was acquired in 2001 for $168 million by Cytyc Corporation. Dr. Hung currently serves as Chairman of the Board of Directors of T-Therapeutics and as a member of the Board of Directors of Novocure.

Dr. Hung received an A.B. summa cum laude in biology from Harvard College and an M.D. Alpha Omega Alpha from the University of California, San Francisco, School of Medicine. He completed simultaneous clinical fellowships in hematology, oncology and transfusion medicine as well as two basic science research fellowships in molecular biology at the University of California, San Francisco, School of Medicine.

What is David Hung's net worth?

The estimated net worth of David Hung is at least $131.00 million as of April 4th, 2025. Hung owns 58,481,054 shares of Nuvation Bio stock worth more than $130,997,561 as of May 1st. This net worth estimate does not reflect any other investments that Hung may own. Additionally, Hung receives a salary of $1,000,000.00 as CEO at Nuvation Bio. Learn More about David Hung's net worth.

How old is David Hung?

Hung is currently 66 years old. There are 8 older executives and no younger executives at Nuvation Bio. Learn More on David Hung's age.

What is David Hung's salary?

As the CEO of Nuvation Bio Inc., Hung earns $1,000,000.00 per year. Learn More on David Hung's salary.

How do I contact David Hung?

The corporate mailing address for Hung and other Nuvation Bio executives is 1500 BROADWAY SUITE 1401, NEW YORK NY, 10036. Nuvation Bio can also be reached via phone at 332-208-6102 and via email at ir@nuvationbio.com. Learn More on David Hung's contact information.

Has David Hung been buying or selling shares of Nuvation Bio?

During the last ninety days, David Hung has bought $818,000.00 in Nuvation Bio stock. Most recently, on Monday, April 7th, David Hung bought 300,000 shares of Nuvation Bio stock. The stock was acquired at an average cost of $1.62 per share, with a total value of $486,000.00. Following the completion of the transaction, the chief executive officer now directly owns 58,781,054 shares of the company's stock, valued at $95,225,307.48. Learn More on David Hung's trading history.

Who are Nuvation Bio's active insiders?

Nuvation Bio's insider roster includes Kim Blickenstaff (Director), Xiangmin Cui (Director), Jennifer Fox (CFO & Sec. ), David Hung (Founder), David Hung (CEO), Robert Mashal (Director), and Oleg Nodelman (Director). Learn More on Nuvation Bio's active insiders.

Are insiders buying or selling shares of Nuvation Bio?

During the last year, Nuvation Bio insiders bought shares 6 times. They purchased a total of 1,196,778 shares worth more than $2,803,500.47. The most recent insider tranaction occured on April, 7th when CEO David Hung bought 300,000 shares worth more than $486,000.00. Insiders at Nuvation Bio own 29.9% of the company. Learn More about insider trades at Nuvation Bio.

Information on this page was last updated on 4/7/2025.

David Hung Insider Trading History at Nuvation Bio

See Full Table

David Hung Buying and Selling Activity at Nuvation Bio

This chart shows David Hung's buying and selling at Nuvation Bio by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$818kbought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$500k$0$500kTotal Insider BuyingTotal Insider Selling

Nuvation Bio Company Overview

Nuvation Bio logo
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.
Read More

Today's Range

Now: $2.22
Low: $2.20
High: $2.28

50 Day Range

MA: $1.95
Low: $1.65
High: $2.31

2 Week Range

Now: $2.22
Low: $1.54
High: $3.97

Volume

642,810 shs

Average Volume

2,113,341 shs

Market Capitalization

$750.17 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.47